Pure Global
NCT04662151

Phase 1b Study on AT-100 Intervention (rhSP-D) in Preterm Neonates at High Risk for Development of Bronchopulmonary Dysplasia (BPD)

A Phase 1b, Randomized, Open-Label, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)
Airway Therapeutics, Inc.·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bronchopulmonary Dysplasia
Drug/Device/Intervention
AT-100
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Airway Therapeutics, Inc.
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2021
End date
Feb 01, 2022
Enrollment
36 participants
Primary outcome

Safety and tolerability of AT-100

Summary

The purpose of this study is to determine if an investigational drug, AT-100, can reduce the
 occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature, as compared to
 babies born premature who receive an air-sham alone.

ICD-10 classifications
Bronchopulmonary dysplasia originating in the perinatal periodCongenital bronchomalaciaBronchopneumonia, unspecifiedOther congenital malformations of bronchusDiseases of bronchus, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04662151
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04662151 through Pure Global AI's free database. This Phase 1 trial is sponsored by Airway Therapeutics, Inc. and is currently Not yet recruiting. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.